Merck Gains Patent Office Support in Dispute with Halozyme Over Injectable Keytruda Technology

Merck has received support from the U.S. Patent and Trademark Office in its ongoing legal dispute with Halozyme Therapeutics over a new injectable version of its cancer treatment, Keytruda. The development comes as Merck works to introduce an updated formulation of the widely used immunotherapy drug, which has been a cornerstone of its oncology portfolio.

The patent office’s decision centers on the use of enzymes that facilitate subcutaneous injections, a technology at the heart of the disagreement between Merck and Halozyme. Halozyme holds patents related to these enzymes, which are designed to enhance drug delivery by breaking down tissue barriers. Merck’s efforts to develop an injectable form of Keytruda rely on similar technology, prompting Halozyme to challenge Merck’s approach on intellectual property grounds. This latest move by the patent office provides Merck with a favorable position as it seeks to advance its plans for the new formulation amid ongoing litigation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 4, 2025

Related posts:

Groundbreaking Study Reveals Omega-3s May Slow Human Aging ‘Ultra-Rapid’ Testing Identifies Cancer Genetics During Surgery Generic Drug Stability: Long-Term Testing Confirms Product Stability for Shelf Life. FTO Analyses in Biopharma: Stability Testing Ensures Quality and Safety of Generic Drugs

Author

Mark Chiang